Welcome to our dedicated page for RNLXD SEC filings (Ticker: RNLXD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RNLXD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RNLXD's regulatory disclosures and financial reporting.
Renalytix plc’s major shareholder group has fallen below the 5% ownership threshold. Jefferson River Capital LLC and related parties now report beneficial ownership of 19,644,391 Ordinary Shares, or 4.5% of the class, based on 437,018,680 Ordinary Shares outstanding as of November 3, 2025.
The Hamilton E. James 2003 Children's Trust and David R. James each report beneficial ownership of 19,406,043 Ordinary Shares, representing 4.4% of the class. The filing states that each reporting person ceased to be the beneficial owner of more than 5% of Renalytix’s Ordinary Shares on November 3, 2025.